
📢 @TransgeneSA press release @TransgeneSA Reports Continued Clinical Progress and Q3 2026 Financial Update Read the press release shorturl.at/7K60v

Biotech company developping immunotherapeutics against cancer #Individualized #Therapeutic #Vaccine #Immunotherapy #Oncoloytic #Virus

📢 @TransgeneSA press release @TransgeneSA Reports Continued Clinical Progress and Q3 2026 Financial Update Read the press release shorturl.at/7K60v

📢 Communiqué de presse @TransgeneSA @TransgeneSA poursuit ses programmes cliniques et fait le point sur sa situation financière au troisième trimestre 2026 Lire le communiqué de presse shorturl.at/uKNjH

📢 Une étape importante pour BT-001 : le premier patient a été traité avec succès dans l'étude OV-PRIME-R. 🔬 Cette étude initiée par l’Université de Copenhague, évalue BT-001, développé conjointement par @TransgeneSA et @BioInvent. Communiqué de presse shorturl.at/4siGX

📢 An important milestone for BT-001: the first patient has been successfully treated in the OV-PRIME-R trial. 🔬 Initiated by the University of Copenhagen, this IST evaluates BT-001, armed oncolytic virus co-developed by @TransgeneSA and @BioInvent . PR: shorturl.at/MRW1r

📢 Communiqué de presse @TransgeneSA @TransgeneSA présentera des données précliniques au @sitcancer 2026 sur son virus oncolytique innovant ouvrant la voie à une administration systémique Découvrez le poster n°1050 le 7 novembre 👉 shorturl.at/Dm0hM

📢 @TransgeneSA Press Release @TransgeneSA to Present Preclinical Data on Novel Oncolytic Virus at @sitcancer 2026 Supporting its Potential for Systemic Delivery Discover poster #1050 on November 7 👉 Read the press release shorturl.at/4hPFN

🚀 Meeting with the @TransgeneSA Trio at @myESMO 2026 Alessandro Riva, M.D., Chairman and CEO, Emmanuelle Dochy, Chief Medical Officer and James Wentworth, PhD, MBA, Chief Business Officer are attending 📍Let's meet and explore new opportunities together

👍 @TransgeneSA recently published in @FrontiersIn🎉 🚀 This work marks a significant advance in synthetic virology and paves the way for the development of next-generation oncolytic virus candidates. 👉 shorturl.at/ulAfi

🚀 @TransgeneSA is happy to welcome @AnneStehlin as its Chief Quality Officer and Responsible Pharmacist. 🤗 Welcome to Anne in her new role!

🚀 @transgene.bsky.social est heureuse de compter @Anne_Stehlin parmi son équipe en tant que Directrice Qualité et Pharmacienne Responsable. 🤗 Bienvenue à @Anne dans ses nouvelles fonctions !

🎤 @TransgeneSA at the @festofbiologics A big thank you to everyone who joined today's presentations by @Katell_Bidet_Huang, Head of Translational Medicine, and @Simone_Steiner, Chief Technical Officer, and engaged in the discussions.

🎤 @TransgeneSA at the @festofbiologics next week, in Basel 🎉 🗣️ Listen to @katell_bidet_huang, Head of Translationnal Medicine at @TransgeneSA & @simone_steiner, Chief Technical Officer at @TransgeneSA on October 13 at 2 :30 pm and 5:10 pm respectively.

@TransgeneSA présentera un poster sur les données précliniques de son virus oncolytique innovant, le 7 novembre au @sitcancer 2026. 📰 communiqué de presse 👉 shorturl.at/sjJJw

@TransgeneSA to Present a Poster on Preclinical Data from a Novel Oncolytic Virus on November 7, at @sitcancer 2026. 📰 press release 👉 shorturl.at/f4Mun

